Table 5 Serum albumin levels and survival - other cancer sites
First author, year of publication, place | Year of data collection | Study design, Sample size | Cancer type | Groups being compared | RR (95%Cl), p-value | Variables adjusted for |
|---|---|---|---|---|---|---|
Barreto-Andrade JC, 2009, Mexico [87] | January 1986 to May 2006 | Retrospective, 61 | Soft Tissue Sarcoma | Low <3.5 g/dL Normal >=3.5 g/dL | Univariate: p = 0.03 Multivariate: p = 0.02 | Age, sex, obesity, previous biopsy performed, histology, site histologic grade, stage, tumor resectability, tumor size, performance status, surgical risk |
Seve P, 2006, France [47] | January 1, 1998 to December 31, 2004 | Retrospective consecutive case series, 317 | Unknown Primary | Low <3.5 g/dL Normal >=3.5 g/dL | Univariate: Median survival in days Low: 62; Normal: 318; p < 0.0001 Multivariate: 2.70 (1.79-4.07), <.0001 | Age, sex, ACE-27 score, No. of sites, liver metastasis, peritoneal mets, PS, LDH, ALP, hemoglobin, platelets |
Alici S, 2003, Turkey [88] | 1989 to 1998 | Retrospective, 110 | Non-Hodgkin's Lymphoma | Normal Low | Univariate: p = 0.005 Multivariate: p = 0.022 | Age, sex, stage, PS, B symptoms, treatment regimen, remission status, histology, bulky disease, LDH, ESR, extranodal involvement |
Medow MA, 2002, USA [89] | July 1993 to June 1997 | Retrospective consecutive case series, 406 | Head and neck | <3.85 g/dL >=3.85 g/dL | TNM stage IV or recurrent disease Median survival: <3.85 g/dL: 404 days (286-532 days), >=3.85 g/dL: 625 days (536-1032 days) | Age, tumor stage, self-reported functional class, systolic blood pressure, diastolic blood pressure, and BMI |
Ljungberg B, 2000, Sweden [90] | April 1982 to February 1999 | Retrospective consecutive case series, 106 | Renal cell | Continuous variable | Univariate: NA, p = 0.063 Multivariate: 1.01 (0.45 - 2.28), 0.96 | Age, gender, tumor size, PS, solitary metastases, calcium, ESR, nuclear grade, DNA ploidy and vein invasion |
Schwartzbaum JA, 1999, USA [91] | February 1, 1993 to December 31, 1995 | A convenience sample, 24 | Glioblastoma multiforme | 1st Quartile (2.6-3.1 g/dL) 2nd Quartile 3rd Quartile 4th Quartile (3.9-4.4 g/dL) | Multivariate: 2nd= 1.2 3rd= 0.1 4th =0.1 p = 0.007 | Age, sex, chemotherapy, serum iron, radiation |
Aparicio J, 1998, Spain [92] | 1970 to 1993 | Retrospective, 116 | Ewing's sarcoma | Low: <=3.5 g/dL Normal: >3.5 g/dL | Univariate: 5 year survival 48% in normal and 7% in low; median survival 52 months in normal and 6 months in low, p < 0.0001 Multivariate: p = 0.001 | Age, sex, tumor site, maximum tumor diameter, extent of disease, PS, duration of symptoms before diagnosis, systemic symptoms, leukocytes and hemoglobin, ESR, LDH, histologic pattern, percent of tumor necrosis on the initial biopsy specimen |
Citterio G, 1997, Italy [93] | 1988 onwards | Retrospective consecutive case series, 109 | Renal cell | NA | Univariate: p < 0.01 | Age, sex, DFI, PS, stage at diagnosis, grading, number and type of metastatic sites, nephrectomy, blood levels of hemoglobin, creatinine, calcium, LDH, ferritin, ALP, triglycerides |